Orthofix Med Inc Stock Price, News & Analysis

Orthofix Medical Inc (NASDAQ:OFIX) has launched the Opus^™ Mg Set, a synthetic magnesium-based osteoconductive scaffold designed for orthopedic procedures. This innovative product aids in filling non-structural bony voids, enhancing the natural bone-healing process. The Opus Mg Set is available in moldable and injectable forms, providing immediate compressive strength and significant bone remodeling, with preclinical studies indicating over 80% bone remodeling in 26 weeks. This launch reflects Orthofix’s commitment to advancing biologic solutions in orthopedic care.

Orthofix Medical Inc. (NASDAQ:OFIX) announced participation in the Sidoti Virtual Investor Conference on September 23, 2021, at 2:30 p.m. ET. President and CEO Jon Serbousek and CFO Doug Rice will engage in a fireside chat, with one-on-one meetings before and after the session. Interested parties can access the live webcast on the company’s website. Orthofix focuses on innovative medical solutions in spine and orthopedics, distributing products in over 60 countries. For more information, visit www.orthofix.com.

Orthofix Medical Inc. (NASDAQ:OFIX) announces the first U.S. pediatric patient implanted with the Fitbone intramedullary lengthening system. This FDA-cleared solution is designed for limb lengthening of the femur and tibia, available in sizes 9mm, 11mm, and 13mm. The Fitbone system is now compatible with the OrthoNext digital platform, enhancing preoperative planning. The system has been successfully used in over 3,500 cases globally, reflecting Orthofix's commitment to improving patient outcomes in orthopedic care.

Orthofix Medical Inc. (NASDAQ:OFIX) reported Q2 2021 financial results, with net sales of $121 million and EPS of $0.12. Adjusted EPS rose to $0.32, reflecting improved performance over pre-COVID levels. Key growth drivers include the M6-C cervical disc and FITBONE lengthening system. Gross profit increased to $94 million, with a gross margin of 77.4%. However, cash flow from operations fell to $0.3 million. The 2021 outlook anticipates net sales between $468 million and $474 million, representing a 15.1% to 16.6% increase.

Orthofix Medical Inc (NASDAQ:OFIX) announced the first patient implant in a pivotal FDA clinical study evaluating the M6-C™ artificial cervical disc for two-level cervical radiculopathy. This study will compare the disc's safety and effectiveness against anterior cervical discectomy and fusion (ACDF). A total of 263 patients will be enrolled, aiming for a primary endpoint of overall success at 24 months. The M6-C disc has been implanted over 55,000 times globally, reinforcing its position as a promising alternative to cervical fusion.

Orthofix Medical Inc. (NASDAQ:OFIX) has announced it will release its second quarter 2021 financial results on Friday, August 6, 2021, before the market opens. The company’s President, Jon Serbousek, and CFO, Doug Rice, will conduct a conference call at 8:30 a.m. ET to discuss the results. Interested parties can access the call by dialing specific numbers or through a webcast available on the company's investor relations website.

Orthofix Medical Inc. (NASDAQ:OFIX) has launched the fiberFUSE™ Strip, a new bone-graft solution for spinal procedures. This innovative product is composed entirely of natural bone and is designed for optimized application in cervical and lumbar surgeries. The fiberFUSE Strip enables cellular ingrowth and new bone formation due to its unique composition. The technology was developed to provide convenience and effectiveness for spine surgeons and their patients. MTF Biologics is the exclusive processor of this product, ensuring high-quality standards through validated aseptic processing.

Orthofix Medical Inc. (NASDAQ:OFIX) announced significant findings from a retrospective study published in The International Journal of Spine Surgery, highlighting a 92.7% fusion rate for patients undergoing three- and four-level lumbar arthrodesis surgery with the SpinalStim device. This data, gathered from 55 patients, reinforces the effectiveness of Pulsed Electromagnetic Field Stimulation (PEMF) therapy even among high-risk patients. The device is FDA-approved for lumbar spinal fusion procedures and is supported by the STIM onTrack mobile app, enhancing patient engagement in recovery.

Orthofix Medical Inc (NASDAQ: OFIX) has launched the FORZA Ti PLIF Spacer System in the U.S., designed for enhancing Posterior Lumbar Interbody Fusion (PLIF) procedures. The device is 3D-printed with optimized porosity and features to support bone ingrowth, critical for surgical success. Key features include a large graft window, titanium endplates with 400 micron pores, and a functional gradient porous structure. The FORZA Ti system is part of Orthofix's growing portfolio of innovative 3D-printed titanium products aimed at improving surgical outcomes.